Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct;155 Suppl 1(Suppl 1):61-85.
doi: 10.1002/ijgo.13878.

Cancer of the ovary, fallopian tube, and peritoneum: 2021 update

Jonathan S Berek  1 , Malte Renz  1 , Sean Kehoe  2   3 , Lalit Kumar  4 , Michael Friedlander  5   6
Affiliations
Review

Cancer of the ovary, fallopian tube, and peritoneum: 2021 update

Jonathan S Berek et al. Int J Gynaecol Obstet. 2021 Oct.

Abstract

In 2014, FIGO's Committee for Gynecologic Oncology revised the staging of ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of these malignancies are high-grade serous carcinomas (HGSC). Stage IC is now divided into three categories: IC1 (surgical spill); IC2 (capsule ruptured before surgery or tumor on ovarian or fallopian tube surface); and IC3 (malignant cells in the ascites or peritoneal washings). The updated staging includes a revision of Stage IIIC based on spread to the retroperitoneal lymph nodes alone without intraperitoneal dissemination. This category is now subdivided into IIIA1(i) (metastasis ≤10 mm in greatest dimension), and IIIA1(ii) (metastasis >10 mm in greatest dimension). Stage IIIA2 is now "microscopic extrapelvic peritoneal involvement with or without positive retroperitoneal lymph node" metastasis. This review summarizes the genetics, surgical management, chemotherapy, and targeted therapies for epithelial cancers, and the treatment of ovarian germ cell and stromal malignancies.

Keywords: FIGO Cancer Report; cancer staging; chemotherapy; fallopian tube; ovarian; ovary; peritoneum.

PubMed Disclaimer

Conflict of interest statement

Outside the submitted work, JSB reports institutional research funding received from Tesaro and ImmunoGen, and participation on a Merck Data Safety Monitoring Committee (MK‐7339‐001 ENGOT‐ov43). Outside the submitted work, MF reports institutional research grants received from AstraZeneca, Novartis, and Beigene; consulting fees from AstraZeneca, GSK, MSD, Lilly, Novartis, and Takeda; honoraria for lectures from AstraZeneca, GSK, and ACT Genomics; and participation on an AGITG Data Safety Monitoring Board. All other authors report no conflicts of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Berek JS, Friedlander M, Hacker NF. Epithelial ovarian, fallopian tube, and peritoneal cancer. In: Berek JS, Hacker NF, Eds. Berek and Hacker’s Gynecologic Oncology, 7th edn. Wolters Kluwer Health; 2020.
    1. Scully RE, Young RH, Clements PB. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligaments. Atlas of Tumor Pathology. Third series. Armed Forces Institute of Pathology; 1998.
    1. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31:161‐169. - PubMed
    1. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA‐positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007;25:3985‐3990. - PubMed
    1. Kurman RJ, IeM S. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol. 2008;27:151‐160. - PMC - PubMed